Cellectar Biosciences Inc - Asset Resilience Ratio
Cellectar Biosciences Inc (CLRB) has an Asset Resilience Ratio of 0.28% as of September 2018. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2010–2018)
This chart shows how Cellectar Biosciences Inc's Asset Resilience Ratio has changed over time. Check strategic asset allocation of Cellectar Biosciences Inc to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Cellectar Biosciences Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Cellectar Biosciences Inc market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $55.00K | 0.28% |
| Total Liquid Assets | $55.00K | 0.28% |
Asset Resilience Insights
- Limited Liquidity: Cellectar Biosciences Inc maintains only 0.28% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Cellectar Biosciences Inc Industry Peers by Asset Resilience Ratio
Compare Cellectar Biosciences Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for Cellectar Biosciences Inc (2010–2018)
The table below shows the annual Asset Resilience Ratio data for Cellectar Biosciences Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2018-12-31 | 0.37% | $55.00K | $15.05 Million | -0.06pp |
| 2017-12-31 | 0.43% | $55.00K | $12.87 Million | +0.07pp |
| 2016-12-31 | 0.36% | $55.00K | $15.32 Million | -0.37pp |
| 2015-12-31 | 0.72% | $55.00K | $7.60 Million | +0.31pp |
| 2014-12-31 | 0.41% | $55.00K | $13.42 Million | -0.40pp |
| 2013-12-31 | 0.81% | $55.00K | $6.82 Million | +0.33pp |
| 2012-12-31 | 0.48% | $55.00K | $11.48 Million | -0.04pp |
| 2011-12-31 | 0.52% | $55.00K | $10.56 Million | -22.03pp |
| 2010-12-31 | 22.56% | $555.00K | $2.46 Million | -- |
About Cellectar Biosciences Inc
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with re… Read more